首页 > 市场调查报告书 > 製药

精神疾病

市场调查报告书

商品编码

1136942

抗治疗性忧郁症的市场:各药物类型，各流通管道，各地区-规模，占有率，展望，机会分析，2022年～2030年

Treatment Resistant Depression Market, by Drug Type (Antidepressants Atypical agents, others), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年09月02日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3个工作天内

价格

简介目录

市场动态

增加无机活动，例如组织资助以扩大其在全球抗治疗抑郁症市场的影响力，预计将在预测期内推动市场增长。

本调查的主要特征

本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球抗治疗性忧郁症市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球抗治疗性忧郁症市场的主要参与者之企业简介。
藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
全球抗治疗性忧郁症市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以透过全球抗治疗性忧郁症市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

热图分析
市场占有率分析
- AbbVie Inc.
- Lupin
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Bausch Health Companies Inc.
- Sanofi
- Mallinckrodt
- Johnson & Johnson
- Merck & Co., Inc.
- Viatris Inc.
- Otsuka Holdings Co., Ltd.
- Lundbeck A/S
- AstraZeneca
- Aurobindo Pharma Ltd.

第9章章节

调查手法的介绍
关于出版社

简介目录

Product Code: CMI5196

Depression is a mood disorder that causes a persistent feeling of sadness and a loss of interest. Also called major depressive disorder or clinical depression, it affects how patients feel, think, and behave and can lead to a variety of emotional and physical problems. Patients may have trouble doing normal day-to-day activities. Depression (major depressive disorder) is a common and serious medical illness that negatively affects how patients feel, the way they think, and how they act. Depression causes feelings of sadness and/or a loss of interest in activities patients once enjoyed. It can lead to a variety of emotional and physical problems. There are various drugs available for treatment of depression, such as antidepressants, which are medications that can help relieve symptoms of depression, social anxiety disorder, anxiety disorders, and seasonal affective disorder. The atypical agents, also known as second generation antipsychotics and serotonin-dopamine antagonists, are a group of antipsychotic drugs largely introduced to be used to treat psychiatric conditions.

Market Dynamics

Increasing inorganic activities such as fund raise by organizations in order to expand their presence in the global treatment resistant depression market is expected to drive the market growth over forecast period. For instance, in February 2022, Minded, the specialist in prescribing mental health medication online, announced US$ 25 million in seed funding. Investors included Streamlined Ventures, Link Ventures, The Tiger Fund, Unicorn Ventures, Trousdale Ventures, Gaingels, SALT Fund, TheFund, and the founders of Care.com, Bolt, Gravity Blanket, RXBAR, and Gilt.com, along with venture debt from Western Technology Investment (WTI).

Increasing development of novel therapeutics for the treatment of resistant depression by market players to launch their novel products is expected to drive market growth over forecast period. For instance, in September 2021, XWPharma Ltd., a biopharmaceutical company, announced dosing of subjects in its first-in-human study evaluating XW10508, the company's novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain.

Key features of the study:

This report provides an in-depth analysis of the global treatment resistant depression market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global treatment resistant depression market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global treatment resistant depression market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global treatment resistant depression market

Detailed Segmentation:

Global Treatment Resistant Depression Market, by Drug Type :
- Antidepressants
  - Selective Serotonin Reuptake Inhibitors
  - Serotonin-norepinephrine Reuptake Inhibitors
  - Others
- Atypical agents
- Others
Global Treatment Resistant Depression Market, by Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Treatment Resistant Depression Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- AbbVie Inc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Lupin
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Bausch Health Companies Inc.
- Sanofi
- Mallinckrodt
- Johnson & Johnson
- Merck & Co., Inc.
- Viatris Inc.
- Otsuka Holdings Co., Ltd.
- Lundbeck A/S
- AstraZeneca
- Aurobindo Pharma Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Developments
Industry Trends
Regulatory Scenario
Recent Product Approval/Launches
PEST Analysis
Porter's Analysis

4. Global Treatment Resistant Depression Market- Impact of Coronavirus (COVID-19) Pandemic

Impact on Demand
Impact on Healthcare
Epidemiology

5. Global Treatment Resistant Depression Market, By Drug Type, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Selective Serotonin Reuptake Inhibitors
Serotonin-norepinephrine Reuptake Inhibitors
Others
Atypical agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)

6. Global Treatment Resistant Depression Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)

7. Global Treatment Resistant Depression Market, By Region, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030(%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030 (US$ Mn)
South Africa
Central Africa
North Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- AbbVie Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Lupin
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Eli Lilly and Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- GlaxoSmithKline Plc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Bausch Health Companies Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Sanofi
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Mallinckrodt
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Johnson & Johnson
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Viatris Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Otsuka Holdings Co., Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Lundbeck A/S
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- AstraZeneca
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Aurobindo Pharma Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

9. Section

Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/价格

抗治疗性忧郁症的市场:各药物类型，各流通管道，各地区-规模，占有率，展望，机会分析，2022年～2030年

Treatment Resistant Depression Market, by Drug Type (Antidepressants Atypical agents, others), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

市场动态

本调查的主要特征

目录

第1章调查目的与前提条件

第2章市场展望

第3章市场动态，法规，趋势的分析

第4章抗治疗性忧郁症的全球市场:冠状病毒(COVID-19)疫情的影响

第5章抗治疗性忧郁症的全球市场:各药物类型，2017年～2030年

第6章抗治疗性忧郁症的全球市场:各流通管道，2017年～2030年

第7章抗治疗性忧郁症的全球市场:各地区，2017年～2030年

第8章竞争情形

第9章章节

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Treatment Resistant Depression Market- Impact of Coronavirus (COVID-19) Pandemic

5. Global Treatment Resistant Depression Market, By Drug Type, 2017 - 2030, (US$ Mn)

6. Global Treatment Resistant Depression Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

7. Global Treatment Resistant Depression Market, By Region, 2017 - 2030 (US$ Million)

8. Competitive Landscape

9. Section

抗治疗性忧郁症的市场:各药物类型，各流通管道，各地区-规模，占有率，展望，机会分析，2022年～2030年

Treatment Resistant Depression Market, by Drug Type (Antidepressants Atypical agents, others), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

市场动态

本调查的主要特征

目录

第1章 调查目的与前提条件

第2章 市场展望

第3章 市场动态，法规，趋势的分析

第4章 抗治疗性忧郁症的全球市场:冠状病毒(COVID-19)疫情的影响

第5章 抗治疗性忧郁症的全球市场:各药物类型，2017年～2030年

第6章 抗治疗性忧郁症的全球市场:各流通管道，2017年～2030年

第7章 抗治疗性忧郁症的全球市场:各地区，2017年～2030年

第8章 竞争情形

第9章 章节

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Treatment Resistant Depression Market- Impact of Coronavirus (COVID-19) Pandemic

5. Global Treatment Resistant Depression Market, By Drug Type, 2017 - 2030, (US$ Mn)

6. Global Treatment Resistant Depression Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

7. Global Treatment Resistant Depression Market, By Region, 2017 - 2030 (US$ Million)

8. Competitive Landscape

9. Section

第1章调查目的与前提条件

第2章市场展望

第3章市场动态，法规，趋势的分析

第4章抗治疗性忧郁症的全球市场:冠状病毒(COVID-19)疫情的影响

第5章抗治疗性忧郁症的全球市场:各药物类型，2017年～2030年

第6章抗治疗性忧郁症的全球市场:各流通管道，2017年～2030年

第7章抗治疗性忧郁症的全球市场:各地区，2017年～2030年

第8章竞争情形

第9章章节